Articles

A case study illustrates that identification of changes in monoclonal gammopathy may improve the accurate diagnosis of cardiac amyloidosis subtypes. Read More ›

Early diagnosis before the development of advanced organ disease remains key in improving outcomes in amyloidosis. Read More ›

Researchers have found that cardiac scintigraphy imaging performance may be improved for uncovering transthyretin cardiac amyloidosis using deep learning augmentation of interpretation. Read More ›

Based on postmortem evaluation, cardiac amyloidosis can be detected in more than two-fifths of autopsied hearts of elderly patients aged ≥75 years. Read More ›

Tools to Diagnose and Monitor ATTR-CM
During this discussion, transthyretin amyloidosis specialists will be outlining the diagnostic and prognostic tools that are utilized to help guide treatment decisions for ATTR-CM. Read More ›

Evolving Approaches to Transthyretin Stabilization for Cardiac ATTR
Amyloidosis News presents a discussion on the evolving approaches to transthyretin stabilization for cardiac ATTR. Transthyretin amyloid specialists, Keyur B. Shah, MD, Section Chief of Heart Failure, Virginia Commonwealth University Health and Michel Khouri, MD, Associate Professor of Medicine in Cardiology, Duke University review cardiac ATTR mechanism of disease and discuss proven and potential approaches to TTR stabilization. Read More ›

Utility of Functional Assessments in the Prognosis of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Amy Brownell, MSN, FNP-C, AACC, System Director of Heart Failure, AMITA Health, Chicago, IL; Sarah C. Paciulli, MS, RN, CHFN, NP-C, VCU Health, Richmond, VA; and Lori Roth, MS, PA-C, Advanced Heart Failure Clinic, UT Southwestern Medical Center, Dallas TX, explain the usefulness of the six-minute walk test in clinical practice and to patients. Read More ›

The Importance of Early Diagnosis in ATTR-CM

Addressing Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Through Preservation of Transthyretin
Lori Roth, MS, PA-C, Advanced Heart Failure Clinic, UT Southwestern Medical Center, Dallas, TX; Sarah C. Paciulli, MS, RN, CHFN, NP-C, VCU Health, Richmond, VA; and Amy Brownell, MSN, FNP-C, AACC, System Director of Heart Failure, AMITA Health, Chicago, IL, review the rationale for stabilization as the optimal approach to addressing transthyretin amyloid cardiomyopathy. Read More ›

Adding daratumumab to bortezomib, cyclophosphamide, and dexamethasone led to higher frequencies of hematologic complete response and survival free from major organ deterioration or hematologic progression in patients with newly diagnosed AL. Read More ›

Page 6 of 14

Amyloidosis News
Subscribe to Amyloidosis News

Stay up to date with Amyloidosis News by subscribing to receive the free AMN e‑Newsletter.